[HTML][HTML] Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
L Zhong, Y Li, L Xiong, W Wang, M Wu… - Signal transduction and …, 2021 - nature.com
Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …
Globally approved EGFR inhibitors: Insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism
Targeting the EGFR with small-molecule inhibitors is a confirmed valid strategy in cancer
therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been …
therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been …
Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance
J Wu, Z Lin - International Journal of Molecular Sciences, 2022 - mdpi.com
The advent of precision medicine has brought light to the treatment of non-small cell lung
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …
Nitrogen containing heterocycles as anticancer agents: a medicinal chemistry perspective
Cancer is one of the major healthcare challenges across the globe. Several anticancer
drugs are available on the market but they either lack specificity or have poor safety, severe …
drugs are available on the market but they either lack specificity or have poor safety, severe …
Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities
T Zubair, D Bandyopadhyay - International Journal of Molecular Sciences, 2023 - mdpi.com
Epidermal growth factor receptors (EGFRs) are a class of receptor tyrosine kinase that are
also called ErbB1 and HER1. EGFR tyrosine kinase activity inhibition is considered a …
also called ErbB1 and HER1. EGFR tyrosine kinase activity inhibition is considered a …
PROTAC therapy as a new targeted therapy for lung cancer
Despite recent advances in molecular therapeutics, lung cancer is still a leading cause of
cancer deaths. Currently, limited targeted therapy options and acquired drug resistance …
cancer deaths. Currently, limited targeted therapy options and acquired drug resistance …
EGFR, the Lazarus target for precision oncology in glioblastoma
B Lin, J Ziebro, E Smithberger, KR Skinner… - Neuro …, 2022 - academic.oup.com
The Lazarus effect is a rare condition that happens when someone seemingly dead shows
signs of life. The epidermal growth factor receptor (EGFR) represents a target in the fatal …
signs of life. The epidermal growth factor receptor (EGFR) represents a target in the fatal …
Potentiating therapeutic effects of epidermal growth factor receptor inhibition in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a subset of breast cancer with aggressive
characteristics and few therapeutic options. The lack of an appropriate therapeutic target is a …
characteristics and few therapeutic options. The lack of an appropriate therapeutic target is a …
Immunomodulatory functions of the circ_001678/miRNA-326/ZEB1 axis in non-small cell lung cancer via the regulation of PD-1/PD-L1 pathway
Q Tian, T Wu, X Zhang, K Xu, X Yin… - Human Molecular …, 2022 - academic.oup.com
High-throughput circular RNA (circRNA) sequencing identified circRNA_001678
(circ_001678) as an upregulated circRNA in non-small cell lung cancer (NSCLC) tissues …
(circ_001678) as an upregulated circRNA in non-small cell lung cancer (NSCLC) tissues …
Novel targets, novel treatments: the changing landscape of non-small cell lung cancer
Simple Summary Non-small cell lung cancer treatment has undergone a revolution in the
past decade owing to the discovery of mutations that drive carcinogenesis and the …
past decade owing to the discovery of mutations that drive carcinogenesis and the …